N/A
Manufactured by Ascend Laboratories, LLC
2,368 FDA adverse event reports analyzed
Last updated: 2026-04-15
CEFPROZIL is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Ascend Laboratories, LLC. The most commonly reported adverse reactions for CEFPROZIL include CHRONIC KIDNEY DISEASE, DRUG HYPERSENSITIVITY, COUGH, ACUTE KIDNEY INJURY, RASH. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CEFPROZIL.
Out of 763 classified reports for CEFPROZIL:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 2,368 FDA FAERS reports that mention CEFPROZIL. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include CHRONIC KIDNEY DISEASE, DRUG HYPERSENSITIVITY, COUGH, ACUTE KIDNEY INJURY, RASH, DYSPNOEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Ascend Laboratories, LLC in connection with CEFPROZIL. Always verify the specific product and NDC with your pharmacist.